Article Contents
REVIEW   Open Access     Cite

Iron-based materials for sequential tumor microenvironment reprogramming: From mechanical decompression to immune remodeling

More Information
  • DownLoad: Full size image
    1. The tumor microenvironment creates physical, metabolic, and immune barriers that limit cancer therapy.

      Iron-based materials offer magnetic, catalytic, and immune-regulating functions to address these barriers.

      Sequential microenvironment reprogramming (SMR) links three stages, from transport to immune remodeling.

      Rather than following a fixed sequence, SMR guides interventions based on biological responses.

      Its clinical potential requires reliable biomarkers, patient stratification, and rigorous validation.

  • The tumor microenvironment (TME) is a dynamic ecosystem in which abnormal vasculature, stromal fibrosis, metabolic adaptation, and immune suppression collectively undermine the effectiveness of cancer therapy. Although iron-based materials have traditionally been developed as imaging agents or drug carriers, their magnetic responsiveness, catalytic activity, and immunomodulatory properties now provide opportunities to intervene in multiple components of the TME. We adapt and formalize sequential microenvironment reprogramming (SMR) as a framework that integrates the functions of iron-based materials across three interconnected intervention tiers (T0–T2). T0 represents baseline microenvironment conditioning, improving perfusion and intratumoral transport through magnetically assisted delivery together with antifibrotic or decompressive strategies. This creates a more permissive environment for T1, in which iron-catalyzed redox reactions and ferroptosis are exploited to disrupt tumor metabolic adaptation. T2 extends these local effects toward myeloid remodeling and regional immune activation to support more durable antitumor responses. SMR provides a framework for interpreting current evidence and identifying stage-specific therapeutic opportunities. Transitions between intervention tiers are guided by biological prerequisites rather than a fixed treatment sequence. We discuss the major challenges that remain, including biomarker-guided stage switching, patient stratification, translational feasibility, and the need for rigorous experimental validation of this staged therapeutic strategy.
  • 加载中
  • [1] Mitchell M.J., Billingsley M.M., Haley R.M., et al. (2021). Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20:101−124. DOI:10.1038/s41573-020-0090-8

    View in Article CrossRef Google Scholar

    [2] Shi J., Kantoff P.W., Wooster R., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 17:20−37. DOI:10.1038/nrc.2016.108

    View in Article CrossRef Google Scholar

    [3] Matsumura Y. and Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387-6392. https://aacrjournals.org/cancerres/article/46/12_Part_1/6387/490212/A-New-Concept-for-Macromolecular-Therapeutics-in

    View in Article Google Scholar

    [4] Youn Y.S. and Bae Y.H. (2018). Perspectives on the past, present, and future of cancer nanomedicine. Adv. Drug Deliv. Rev. 130:3−11. DOI:10.1016/j.addr.2018.05.008

    View in Article CrossRef Google Scholar

    [5] Wilhelm S., Tavares A.J., Dai Q., et al. (2016). Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1:16014. DOI:10.1038/natrevmats.2016.14

    View in Article CrossRef Google Scholar

    [6] Fukumura D., Kloepper J., Amoozgar Z., et al. (2018). Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 15:325−340. DOI:10.1038/nrclinonc.2018.29

    View in Article CrossRef Google Scholar

    [7] De Palma M., Biziato D. and Petrova T.V. (2017). Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17:457−474. DOI:10.1038/nrc.2017.51

    View in Article CrossRef Google Scholar

    [8] Jain R.K. (2014). Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26:605−622. DOI:10.1016/j.ccell.2014.10.006

    View in Article CrossRef Google Scholar

    [9] Sahai E., Astsaturov I., Cukierman E., et al. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20:174−186. DOI:10.1038/s41568-019-0238-1

    View in Article CrossRef Google Scholar

    [10] Stylianopoulos T., Martin J.D., Chauhan V.P., et al. (2012). Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. USA 109:15101−15108. DOI:10.1073/pnas.1213353109

    View in Article CrossRef Google Scholar

    [11] Nia H.T., Munn L.L. and Jain R.K. (2020). Physical traits of cancer. Science 370. DOI:10.1126/science.aaz0868.

    View in Article Google Scholar

    [12] Semenza G.L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell 148:399−408. DOI:10.1016/j.cell.2012.01.021

    View in Article CrossRef Google Scholar

    [13] Petrova V., Annicchiarico-Petruzzelli M., Melino G., et al. (2018). The hypoxic tumour microenvironment. Oncogenesis 7:10. DOI:10.1038/s41389-017-0011-9

    View in Article CrossRef Google Scholar

    [14] Pavlova Natalya N. and Thompson Craig B. (2016). The emerging hallmarks of cancer metabolism. Cell Metab. 23:27−47. DOI:10.1016/j.cmet.2015.12.006

    View in Article CrossRef Google Scholar

    [15] Zhang W., Wang P., Yuan G., et al. (2026). Fatty acid metabolic reprogramming in the tumor microenvironment: Unraveling mechanisms and therapeutic prospects. Genes Dis. 13:101772. DOI:10.1016/j.gendis.2025.101772

    View in Article CrossRef Google Scholar

    [16] Joyce J.A. and Fearon D.T. (2015). T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74−80. DOI:10.1126/science.aaa6204

    View in Article CrossRef Google Scholar

    [17] Hinshaw D.C. and Shevde L.A. (2019). The tumor microenvironment innately modulates cancer progression. Cancer Res. 79:4557−4566. DOI:10.1158/0008-5472.Can-18-3962

    View in Article CrossRef Google Scholar

    [18] Binnewies M., Roberts E.W., Kersten K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24:541−550. DOI:10.1038/s41591-018-0014-x

    View in Article CrossRef Google Scholar

    [19] Anderson N.M. and Simon M.C. (2020). The tumor microenvironment. Curr. Biol. 30:R921−R925. DOI:10.1016/j.cub.2020.06.081

    View in Article CrossRef Google Scholar

    [20] Valkenburg K.C., de Groot A.E. and Pienta K.J. (2018). Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 15:366−381. DOI:10.1038/s41571-018-0007-1

    View in Article CrossRef Google Scholar

    [21] Martin J.D., Cabral H., Stylianopoulos T., et al. (2020). Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17:251−266. DOI:10.1038/s41571-019-0308-z

    View in Article CrossRef Google Scholar

    [22] Liu Y., Sun D., Li W., et al. (2026). Nanomedicine-mediated modulation of tumor metabolism for enhanced immunotherapy. J. Control. Release 390:114587. DOI:10.1016/j.jconrel.2025.114587

    View in Article CrossRef Google Scholar

    [23] Jain R.K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58−62. DOI:10.1126/science.1104819

    View in Article CrossRef Google Scholar

    [24] Galluzzi L., Buqué A., Kepp O., et al. (2017). Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17:97−111. DOI:10.1038/nri.2016.107

    View in Article CrossRef Google Scholar

    [25] Sengupta S., Eavarone D., Capila I., et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568−572. DOI:10.1038/nature03794

    View in Article CrossRef Google Scholar

    [26] Mpekris F., Panagi M., Voutouri C., et al. (2021). Normalizing the microenvironment overcomes vessel compression and resistance to nano-immunotherapy in breast cancer lung metastasis. Adv. Sci. (Weinh) 8:2001917. DOI:10.1002/advs.202001917

    View in Article CrossRef Google Scholar

    [27] Mpekris F., Voutouri C., Baish J.W., et al. (2020). Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc. Natl. Acad. Sci. USA 117:3728−3737. DOI:10.1073/pnas.1919764117

    View in Article CrossRef Google Scholar

    [28] Yu Y., Song Z., Zhu A., et al. (2026). Sequential tumor microenvironment reprogramming by nanoplatform potentiates sonodynamic-chemodynamic therapy and immune checkpoint blockade in breast cancer. Adv. Sci. (Weinh) 13:e12135. DOI:10.1002/advs.202512135

    View in Article CrossRef Google Scholar

    [29] Yu E. Y., Bishop M., Zheng B., et al. (2017). Magnetic particle imaging: A novel in vivo imaging platform for cancer detection. Nano Lett. 17:1648−1654. DOI:10.1021/acs.nanolett.6b04865

    View in Article CrossRef Google Scholar

    [30] Bulte J.W. and Kraitchman D.L. (2004). Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17:484−499. DOI:10.1002/nbm.924

    View in Article CrossRef Google Scholar

    [31] Yang W. S., SriRamaratnam R., Welsch M.E., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317−331. DOI:10.1016/j.cell.2013.12.010

    View in Article CrossRef Google Scholar

    [32] Huo M., Wang L., Chen Y., et al. (2017). Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat. Commun. 8:357. DOI:10.1038/s41467-017-00424-8

    View in Article CrossRef Google Scholar

    [33] Tang Z., Liu Y., He M., et al. (2019). Chemodynamic therapy: Tumour microenvironment-mediated fenton and fenton-like reactions. Angew. Chem. Int. Ed. 58:946−956. DOI:10.1002/anie.201805664

    View in Article CrossRef Google Scholar

    [34] Dixon S.J., Lemberg K.M., Lamprecht M.R., et al. (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149:1060−1072. DOI:10.1016/j.cell.2012.03.042

    View in Article CrossRef Google Scholar

    [35] Jiang X., Stockwell B.R. and Conrad M. (2021). Ferroptosis: Mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22:266−282. DOI:10.1038/s41580-020-00324-8

    View in Article CrossRef Google Scholar

    [36] Wan X., Song L., Pan W., et al. (2020). Tumor-targeted cascade nanoreactor based on metal-organic frameworks for synergistic ferroptosis-starvation anticancer therapy. ACS Nano 14:11017−11028. DOI:10.1021/acsnano.9b07789

    View in Article CrossRef Google Scholar

    [37] Xue C.C., Li M.H., Zhao Y., et al. (2020). Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO(3) nanoformulation triggers ferroptosis in target tumor cells. Sci. Adv. 6:eaax1346. DOI:10.1126/sciadv.aax1346

    View in Article CrossRef Google Scholar

    [38] Chen X. and Song E. (2019). Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18:99−115. DOI:10.1038/s41573-018-0004-1

    View in Article CrossRef Google Scholar

    [39] Diop-Frimpong B., Chauhan V.P., Krane S., et al. (2011). Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA 108:2909−2914. DOI:10.1073/pnas.1018892108

    View in Article CrossRef Google Scholar

    [40] Shapiro B., Kulkarni S., Nacev A., et al. (2015). Open challenges in magnetic drug targeting. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7:446−457. DOI:10.1002/wnan.1311

    View in Article CrossRef Google Scholar

    [41] Liu J.F., Lan Z., Ferrari C., et al. (2020). Use of oppositely polarized external magnets to improve the accumulation and penetration of magnetic nanocarriers into solid tumors. ACS Nano 14:142−152. DOI:10.1021/acsnano.9b05660

    View in Article CrossRef Google Scholar

    [42] Kim D.H., Rozhkova E.A., Ulasov I.V., et al. (2010). Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat. Mater. 9:165−171. DOI:10.1038/nmat2591

    View in Article CrossRef Google Scholar

    [43] Cheng Y., Muroski M.E., Petit D.C.M.C., et al. (2016). Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma. J. Control. Release 223:75−84. DOI:10.1016/j.jconrel.2015.12.028

    View in Article CrossRef Google Scholar

    [44] Shen Y., Wu C., Uyeda T.Q.P., et al. (2017). Elongated nanoparticle aggregates in cancer cells for mechanical destruction with low frequency rotating magnetic field. Theranostics 7:1735−1748. DOI:10.7150/thno.18352

    View in Article CrossRef Google Scholar

    [45] Chauhan V.P., Boucher Y., Ferrone C.R., et al. (2014). Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26:14−15. DOI:10.1016/j.ccr.2014.06.003

    View in Article CrossRef Google Scholar

    [46] Gu Z., Liu T., Liu C., et al. (2021). Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities. Nano Lett. 21:6471−6479. DOI:10.1021/acs.nanolett.1c01401

    View in Article CrossRef Google Scholar

    [47] Zanganeh S., Hutter G., Spitler R., et al. (2016). Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11:986−994. DOI:10.1038/nnano.2016.168

    View in Article CrossRef Google Scholar

    [48] Recalcati S., Locati M., Marini A., et al. (2010). Differential regulation of iron homeostasis during human macrophage polarized activation. Eur. J. Immunol. 40:824−835. DOI:10.1002/eji.200939889

    View in Article CrossRef Google Scholar

    [49] Costa da Silva M., Breckwoldt M.O., Vinchi F., et al. (2017). Iron induces anti-tumor activity in tumor-associated macrophages. Front. Immunol. 8:1479. DOI:10.3389/fimmu.2017.01479

    View in Article CrossRef Google Scholar

    [50] Gu Z., Liu T., Tang J., et al. (2019). Mechanism of iron oxide-induced macrophage activation: The impact of composition and the underlying signaling pathway. J. Am. Chem. Soc. 141:6122−6126. DOI:10.1021/jacs.8b10904

    View in Article CrossRef Google Scholar

    [51] Jansen C.S., Prokhnevska N., Master V.A., et al. (2019). An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576:465−470. DOI:10.1038/s41586-019-1836-5

    View in Article CrossRef Google Scholar

    [52] Sautès-Fridman C., Petitprez F., Calderaro J., et al. (2019). Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19:307−325. DOI:10.1038/s41568-019-0144-6

    View in Article CrossRef Google Scholar

    [53] Schumacher T.N. and Thommen D.S. (2022). Tertiary lymphoid structures in cancer. Science 375:eabf9419. DOI:10.1126/science.abf9419

    View in Article CrossRef Google Scholar

    [54] Helmink B.A., Reddy S.M., Gao J., et al. (2020). B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577:549−555. DOI:10.1038/s41586-019-1922-8

    View in Article CrossRef Google Scholar

    [55] Cabrita R., Lauss M., Sanna A., et al. (2020). Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577:561−565. DOI:10.1038/s41586-019-1914-8

    View in Article CrossRef Google Scholar

    [56] Petitprez F., de Reyniès A., Keung E.Z., et al. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature 577:556−560. DOI:10.1038/s41586-019-1906-8

    View in Article CrossRef Google Scholar

    [57] Stylianopoulos T., Martin J.D., Snuderl M., et al. (2013). Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 73:3833−3841. DOI:10.1158/0008-5472.Can-12-4521

    View in Article CrossRef Google Scholar

    [58] Brand A., Singer K., Koehl G.E., et al. (2016). LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24:657−671. DOI:10.1016/j.cmet.2016.08.011

    View in Article CrossRef Google Scholar

    [59] Recalcati S., Locati M., Gammella E., et al. (2012). Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. Autoimmun. Rev. 11:883−889. DOI:10.1016/j.autrev.2012.03.003

    View in Article CrossRef Google Scholar

    [60] Manz D.H., Blanchette N.L., Paul B.T., et al. (2016). Iron and cancer: Recent insights. Ann. N. Y. Acad. Sci. 1368:149−161. DOI:10.1111/nyas.13008

    View in Article CrossRef Google Scholar

    [61] Yang Y., Liu Y., Song L., et al. (2023). Iron oxide nanoparticle-based nanocomposites in biomedical application. Trends Biotechnol. 41:1471−1487. DOI:10.1016/j.tibtech.2023.06.001

    View in Article CrossRef Google Scholar

    [62] Chen G., Roy I., Yang C., et al. (2016). Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 116:2826−2885. DOI:10.1021/acs.chemrev.5b00148

    View in Article CrossRef Google Scholar

    [63] Lim E.K., Kim T., Paik S., et al. (2015). Nanomaterials for theranostics: Recent advances and future challenges. Chem. Rev. 115:327−394. DOI:10.1021/cr300213b

    View in Article CrossRef Google Scholar

    [64] Gleich B. and Weizenecker J. (2005). Tomographic imaging using the nonlinear response of magnetic particles. Nature 435:1214−1217. DOI:10.1038/nature03808

    View in Article CrossRef Google Scholar

    [65] Makela A.V., Gaudet J.M., Schott M.A., et al. (2020). Magnetic particle imaging of macrophages associated with cancer: Filling the voids left by iron-based magnetic resonance imaging. Mol. Imaging Biol. 22:958−968. DOI:10.1007/s11307-020-01473-0

    View in Article CrossRef Google Scholar

    [66] Park S.J., Han S.R., Kang Y.H., et al. (2022). In vivo preclinical tumor-specific imaging of superparamagnetic iron oxide nanoparticles using magnetic particle imaging for cancer diagnosis. Int. J. Nanomedicine 17:3711−3722. DOI:10.2147/ijn.S372494

    View in Article CrossRef Google Scholar

    [67] Dadfar S.M., Camozzi D., Darguzyte M., et al. (2020). Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance. J. Nanobiotechnology 18:22. DOI:10.1186/s12951-020-0580-1

    View in Article CrossRef Google Scholar

    [68] Kumar P.P.P., Nafiujjaman M., Makela A.V., et al. (2025). Development of iron oxide nanochains as a sensitive magnetic particle imaging tracer for cancer detection. ACS Appl. Mater. Interfaces 17:20859−20871. DOI:10.1021/acsami.5c00332

    View in Article CrossRef Google Scholar

    [69] Ejima H., Richardson J.J., Liang K., et al. (2013). One-step assembly of coordination complexes for versatile film and particle engineering. Science 341:154−157. DOI:10.1126/science.1237265

    View in Article CrossRef Google Scholar

    [70] Zhang C., Bu W., Ni D., et al. (2016). Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton reaction. Angew. Chem. Int. Ed. 55:2101−2106. DOI:10.1002/anie.201510031

    View in Article CrossRef Google Scholar

    [71] Yang G., Xu L., Chao Y., et al. (2017). Hollow MnO(2) as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat. Commun. 8:902. DOI:10.1038/s41467-017-01050-0

    View in Article CrossRef Google Scholar

    [72] Wang C., Guan Y., Lv M., et al. (2018). Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48:675−687.e677. DOI:10.1016/j.immuni.2018.03.017

    View in Article CrossRef Google Scholar

    [73] Lin L.-S., Huang T., Song J., et al. (2019). Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy. J. Am. Chem. Soc. 141:9937−9945. DOI:10.1021/jacs.9b03457

    View in Article CrossRef Google Scholar

    [74] Tsvetkov P., Coy S., Petrova B., et al. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375:1254−1261. DOI:10.1126/science.abf0529

    View in Article CrossRef Google Scholar

    [75] Nam J., Son S., Ochyl L.J., et al. (2018). Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat. Commun. 9:1074. DOI:10.1038/s41467-018-03473-9

    View in Article CrossRef Google Scholar

    [76] Zheng P., Ding B., Shi R., et al. (2021). A Multichannel Ca(2+) Nanomodulator for multilevel mitochondrial destruction-mediated cancer therapy. Adv. Mater. 33:e2007426. DOI:10.1002/adma.202007426

    View in Article CrossRef Google Scholar

    [77] Rhim A.D., Oberstein P.E., Thomas D.H., et al. (2014). Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735−747. DOI:10.1016/j.ccr.2014.04.021

    View in Article CrossRef Google Scholar

    [78] Provenzano P.P., Cuevas C., Chang A.E., et al. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418−429. DOI:10.1016/j.ccr.2012.01.007

    View in Article CrossRef Google Scholar

    [79] Özdemir B.C., Pentcheva-Hoang T., Carstens J.L., et al. (2014). Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719-734. DOI:10.1016/j.ccr.2014.04.005

    View in Article Google Scholar

    [80] Zhang Z., Chen X., Zhang B., et al. (2026). Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets. Biochim. Biophys. Acta Rev. Cancer 1881:189517. DOI:10.1016/j.bbcan.2025.189517

    View in Article CrossRef Google Scholar

    [81] Heldin C.H., Rubin K., Pietras K., et al. (2004). High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4:806−813. DOI:10.1038/nrc1456

    View in Article CrossRef Google Scholar

    [82] Chauhan V.P., Martin J.D., Liu H., et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4:2516. DOI:10.1038/ncomms3516

    View in Article CrossRef Google Scholar

    [83] Tian L., Goldstein A., Wang H., et al. (2017). Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544:250−254. DOI:10.1038/nature21724

    View in Article CrossRef Google Scholar

    [84] O'Connor J.P., Aboagye E.O., Adams J.E., et al. (2017). Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol. 14:169−186. DOI:10.1038/nrclinonc.2016.162

    View in Article CrossRef Google Scholar

    [85] Winkler J., Abisoye-Ogunniyan A., Metcalf K.J., et al. (2020). Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11:5120. DOI:10.1038/s41467-020-18794-x

    View in Article CrossRef Google Scholar

    [86] Levental K.R., Yu H., Kass L., et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891−906. DOI:10.1016/j.cell.2009.10.027

    View in Article CrossRef Google Scholar

    [87] Kalluri R. (2016). The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16:582−598. DOI:10.1038/nrc.2016.73

    View in Article CrossRef Google Scholar

    [88] Huang Z., Chen J., Zhu T., et al. (2025). Cancer-associated fibroblasts in the tumor microenvironment: Heterogeneity, crosstalk mechanisms, and therapeutic implications. Mol. Cancer 25:19. DOI:10.1186/s12943-025-02533-1

    View in Article CrossRef Google Scholar

    [89] Hakim N., Patel R., Devoe C., et al. (2019). Why HALO 301 failed and implications for treatment of pancreatic cancer. Pancreas (Fairfax) 3:e1−e4. DOI:10.17140/POJ-3-e010

    View in Article CrossRef Google Scholar

    [90] Cai W., Chen Y., Dai S., et al. (2025). Hyaluronic acid and its role in pancreatic cancer: Mechanisms of tumor progression, drug resistance, and therapeutic targeting. Pharmacol Res. 221:107958. DOI:10.1016/j.phrs.2025.107958

    View in Article CrossRef Google Scholar

    [91] Li L., Wen J., Xu H., et al. (2026). ECM-responsive nanomedicine to enhance immunotherapy in pancreatic cancer. Colloids Surf. B Biointerfaces 260:115356. DOI:10.1016/j.colsurfb.2025.115356

    View in Article CrossRef Google Scholar

    [92] Song G., Chen Y., Liang C., et al. (2016). Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-Z element and enzyme delivery for enhancing radiotherapy. Adv. Mater. 28:7143−7148. DOI:10.1002/adma.201602111

    View in Article CrossRef Google Scholar

    [93] Chen Q., Feng L., Liu J., et al. (2016). Intelligent albumin-MnO2 nanoparticles as pH-/H2O2 -responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy. Adv. Mater. 28:7129−7136. DOI:10.1002/adma.201601902

    View in Article CrossRef Google Scholar

    [94] Cheng Y., Cheng H., Jiang C., et al. (2015). Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat. Commun. 6:8785. DOI:10.1038/ncomms9785

    View in Article CrossRef Google Scholar

    [95] Gao S., Lin H., Zhang H., et al. (2019). Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction. Adv. Sci. (Weinh) 6:1801733. DOI:10.1002/advs.201801733

    View in Article CrossRef Google Scholar

    [96] Chen H., Tian J., He W., et al. (2015). H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J. Am. Chem. Soc. 137:1539−1547. DOI:10.1021/ja511420n

    View in Article CrossRef Google Scholar

    [97] Yang L., Zhang W.H., Li Y., et al. (2025). Oxygen nanobubbles enhance ICG/Fe(III)-mediated dual-modal therapy to induce ferroptosis in tumor treatment. ACS Appl. Mater. Interfaces 17:11718−11730. DOI:10.1021/acsami.4c19604

    View in Article CrossRef Google Scholar

    [98] Prasad S.B., Shinde A., Srinivasrao D.A., et al. (2025). Metal-organic frameworks as therapeutic chameleons: Revolutionizing the cancer therapy employing novel nanoarchitectonics. Asian J. Pharm. Sci. 20:101054. DOI:10.1016/j.ajps.2025.101054

    View in Article CrossRef Google Scholar

    [99] Jiao L., Yan H., Wu Y., et al. (2020). When nanozymes meet single-atom catalysis. Angew. Chem. Int. Ed. 59:2565−2576. DOI:10.1002/anie.201905645

    View in Article CrossRef Google Scholar

    [100] Huang L., Chen J., Gan L., et al. (2019). Single-atom nanozymes. Sci. Adv. 5:eaav5490. DOI:10.1126/sciadv.aav5490

    View in Article CrossRef Google Scholar

    [101] Horcajada P., Chalati T., Serre C., et al. (2010). Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9:172−178. DOI:10.1038/nmat2608

    View in Article CrossRef Google Scholar

    [102] Ghaemi B. and Javad Hajipour M. (2023). Tumor acidic environment directs nanoparticle impacts on cancer cells. J. Colloid Interface Sci. 634:684−692. DOI:10.1016/j.jcis.2022.12.019

    View in Article CrossRef Google Scholar

    [103] Liu Y., Cai X., Liu J., et al. (2025). The role of redox homeostasis in tumor progression: Implications for cancer therapy. Acta Biomater. 204:156−186. DOI:10.1016/j.actbio.2025.07.067

    View in Article CrossRef Google Scholar

    [104] Doll S., Proneth B., Tyurina Y.Y., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13:91−98. DOI:10.1038/nchembio.2239

    View in Article CrossRef Google Scholar

    [105] Kagan V.E., Mao G., Qu F., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13:81−90. DOI:10.1038/nchembio.2238

    View in Article CrossRef Google Scholar

    [106] Hu Y., Li Z., Li M., et al. (2025). Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. Mol. Cell 85:4602−4620.e4609. DOI:10.1016/j.molcel.2025.11.023

    View in Article CrossRef Google Scholar

    [107] Meng X., Deng J., Liu F., et al. (2019). Triggered all-active metal organic framework: Ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 19:7866−7876. DOI:10.1021/acs.nanolett.9b02904

    View in Article CrossRef Google Scholar

    [108] Zhao Y., Yang S., Huang L., et al. (2025). MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation. Clin. Transl. Med. 15:e70495. DOI:10.1002/ctm2.70495

    View in Article CrossRef Google Scholar

    [109] Hai Y., Lin R., Liao W., et al. (2025). Dihydroorotate dehydrogenase inhibition activates STING pathway and pyroptosis to enhance NK cell-dependent tumor immunotherapy. Mol. Biomed. 6:87. DOI:10.1186/s43556-025-00339-7

    View in Article CrossRef Google Scholar

    [110] Ma C., Han L., Yao H., et al. (2026). Modulating G6PD/PGD to overcome FSP1/DHODH-mediated ferroptosis defence: A novel oridonin derivative suppresses liver cancer. Br. J. Pharmacol. 183:249−267. DOI:10.1111/bph.70160

    View in Article CrossRef Google Scholar

    [111] Li W., Panacek D., Xie Q., et al. (2025). Precision fishing for enzyme-like materials: Identifying and engineering mesoporous catalytic sites for ferroptosis induction. Nano Lett. 25:11356−11364. DOI:10.1021/acs.nanolett.5c02476

    View in Article CrossRef Google Scholar

    [112] Stockwell B.R., Friedmann Angeli J.P., Bayir H., et al. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171:273−285. DOI:10.1016/j.cell.2017.09.021

    View in Article CrossRef Google Scholar

    [113] Stockwell B.R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185:2401−2421. DOI:10.1016/j.cell.2022.06.003

    View in Article CrossRef Google Scholar

    [114] Dixon S.J. and Stockwell B.R. (2019). The hallmarks of ferroptosis. Annu. Rev. Cancer Biol. 3:35−54. DOI:10.1146/annurev-cancerbio-030518-055844

    View in Article CrossRef Google Scholar

    [115] Lei G., Zhuang L. and Gan B. (2022). Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22:381−396. DOI:10.1038/s41568-022-00459-0

    View in Article CrossRef Google Scholar

    [116] Hangauer M.J., Viswanathan V.S., Ryan M.J., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551:247−250. DOI:10.1038/nature24297

    View in Article CrossRef Google Scholar

    [117] Shen Z., Liu T., Li Y., et al. (2018). Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano 12:11355−11365. DOI:10.1021/acsnano.8b06201

    View in Article CrossRef Google Scholar

    [118] Su L., Yang S., Yuan H., et al. (2026). Cell membrane biomimetic drug delivery systems based on ferroptosis mechanism for anticancer treatment. Adv. Healthc. Mater. 15:e04993. DOI:10.1002/adhm.202504993

    View in Article CrossRef Google Scholar

    [119] Gao Y., Xu J., Lai Y., et al. (2025). 2D nanomaterial-triggered ferroptosis in cancer therapy. J. Nanobiotechnology 24:81. DOI:10.1186/s12951-025-03975-x

    View in Article CrossRef Google Scholar

    [120] Ye L.F., Chaudhary K.R., Zandkarimi F., et al. (2020). Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem. Biol. 15:469−484. DOI:10.1021/acschembio.9b00939

    View in Article CrossRef Google Scholar

    [121] Lang X., Green M.D., Wang W., et al. (2019). Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9:1673−1685. DOI:10.1158/2159-8290.Cd-19-0338

    View in Article CrossRef Google Scholar

    [122] Lei G., Zhang Y., Koppula P., et al. (2020). The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 30:146−162. DOI:10.1038/s41422-019-0263-3

    View in Article CrossRef Google Scholar

    [123] Zhu T., Shi L., Yu C., et al. (2019). Ferroptosis promotes photodynamic therapy: Supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics 9:3293−3307. DOI:10.7150/thno.32867

    View in Article CrossRef Google Scholar

    [124] Bae C., Hernández Millares R., Ryu S., et al. (2024). Synergistic effect of ferroptosis-inducing nanoparticles and X-ray irradiation combination therapy. Small 20:e2310873. DOI:10.1002/smll.202310873

    View in Article CrossRef Google Scholar

    [125] Duo K., Feng X., Tian X., et al. (2025). Ferroptosis inhibitors: Mechanisms of action and therapeutic potential. Cell. Mol. Life Sci. 82:441. DOI:10.1007/s00018-025-05958-5

    View in Article CrossRef Google Scholar

    [126] Tang D., Chen X., Kang R., et al. (2021). Ferroptosis: Molecular mechanisms and health implications. Cell Res. 31:107−125. DOI:10.1038/s41422-020-00441-1

    View in Article CrossRef Google Scholar

    [127] Hirayama T., Niwa M., Hirosawa S., et al. (2020). High-throughput screening for the discovery of iron homeostasis modulators using an extremely sensitive fluorescent probe. ACS Sens. 5:2950−2958. DOI:10.1021/acssensors.0c01445

    View in Article CrossRef Google Scholar

    [128] Wiernicki B., Maschalidi S., Pinney J., et al. (2022). Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13:3676. DOI:10.1038/s41467-022-31218-2

    View in Article CrossRef Google Scholar

    [129] Ma X., Xiao L., Liu L., et al. (2021). CD36-mediated ferroptosis dampens intratumoral CD8(+) T cell effector function and impairs their antitumor ability. Cell Metab. 33:1001−1012.e1005. DOI:10.1016/j.cmet.2021.02.015

    View in Article CrossRef Google Scholar

    [130] Xu S., Chaudhary O., Rodríguez-Morales P., et al. (2021). Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8(+) T cells in tumors. Immunity 54:1561−1577.e1567. DOI:10.1016/j.immuni.2021.05.003

    View in Article CrossRef Google Scholar

    [131] Kim R., Hashimoto A., Markosyan N., et al. (2022). Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612:338−346. DOI:10.1038/s41586-022-05443-0

    View in Article CrossRef Google Scholar

    [132] Liu D., Ling Y., Liu W., et al. (2025). Ultrasound-responsive micro/nanobubbles based intelligent theranostic systems for precision tumor therapy. J. Nanobiotechnology 24:83. DOI:10.1186/s12951-025-03959-x

    View in Article CrossRef Google Scholar

    [133] Liu J., Dong R., Yuan B., et al. (2025). Immune cells dying from ferroptosis: Mechanisms and therapeutic opportunities. Cell Death Dis. 16:878. DOI:10.1038/s41419-025-08204-9

    View in Article CrossRef Google Scholar

    [134] Galluzzi L., Kepp O., Zitvogel L., et al. (2026). Cancer cell death: Cell-autonomous and immunogenic dimensions. Cancer Cell 44:281−305. DOI:10.1016/j.ccell.2025.12.005

    View in Article CrossRef Google Scholar

    [135] Obeid M., Tesniere A., Ghiringhelli F., et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13:54−61. DOI:10.1038/nm1523

    View in Article CrossRef Google Scholar

    [136] Tang D., Kepp O. and Kroemer G. (2020). Ferroptosis becomes immunogenic: Implications for anticancer treatments. Oncoimmunology 10:1862949. DOI:10.1080/2162402x.2020.1862949

    View in Article CrossRef Google Scholar

    [137] Krysko D.V., Garg A.D., Kaczmarek A., et al. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12:860−875. DOI:10.1038/nrc3380

    View in Article CrossRef Google Scholar

    [138] Efimova I., Catanzaro E., Van der Meeren L., et al. (2020). Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8. DOI:10.1136/jitc-2020-001369.

    View in Article Google Scholar

    [139] Wang W., Green M., Choi J.E., et al. (2019). CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569:270−274. DOI:10.1038/s41586-019-1170-y

    View in Article CrossRef Google Scholar

    [140] Liao P., Wang W., Wang W., et al. (2022). CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40:365−378.e366. DOI:10.1016/j.ccell.2022.02.003

    View in Article CrossRef Google Scholar

    [141] Huang Z., Zhou H., Huang S., et al. (2026). Amifostine-iron nanoparacrystalline for tumor-selective immunogenic ferroptosis. Nano Lett. 26:278−287. DOI:10.1021/acs.nanolett.5c05065

    View in Article CrossRef Google Scholar

    [142] Son S.W., Lee H.J., Kang N., et al. (2025). The E2F1-HMGCR axis promotes ferroptosis resistance in immune refractory tumor cells. Nat. Commun. 16:10849. DOI:10.1038/s41467-025-66282-x

    View in Article CrossRef Google Scholar

    [143] Hu K., Li J., Chen K., et al. (2025). Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Cell Death Discov. 12:28. DOI:10.1038/s41420-025-02869-z

    View in Article CrossRef Google Scholar

    [144] Zhang J., Jin X., Abulaihaiti M., et al. (2025). Hypoxic tumor exosomes suppress macrophage inflammation and ferroptosis via NDUFV2 to enhance bystander tumor radioresistance. Cell Death Dis. 17:109. DOI:10.1038/s41419-025-08357-7

    View in Article CrossRef Google Scholar

    [145] Li W., Liang L., Liu S., et al. (2025). Inhibin beta A drives colorectal cancer progression through macrophage M2 polarization and mitochondria-dependent ferroptosis suppression. Signal Transduct. Target. Ther. 10:420. DOI:10.1038/s41392-025-02518-y

    View in Article CrossRef Google Scholar

    [146] He Q. and Zhang L. (2025). Nanozyme-driven remodeling of the immune microenvironment: From catalytic therapy to precise immune regulation. Nanoscale 17:25947−25963. DOI:10.1039/d5nr03420e

    View in Article CrossRef Google Scholar

    [147] Ren Y., Cui Y., Wang Z., et al. (2025). ALDH3A2 negatively orchestrates gastric cancer progression through a synergistic induction of ferroptosis and ferroptosis-driven macrophage reprogramming. Cell Death Dis. 17:97. DOI:10.1038/s41419-025-08364-8

    View in Article CrossRef Google Scholar

    [148] Hefetz R., Lianski S., Ghantous L., et al. (2025). Macrophages rescue cells from ferroptotic death. Cell Death Dis. 17:66. DOI:10.1038/s41419-025-08277-6

    View in Article CrossRef Google Scholar

    [149] Wang Z., Xu W., Zhao L., et al. (2026). IL4I1+ Macrophages and TDO2+ myofibroblasts drive AhR-mediated immunosuppression and ferroptosis resistance in solid predominant lung adenocarcinoma. Adv. Sci. (Weinh) 13:e13606. DOI:10.1002/advs.202513606

    View in Article CrossRef Google Scholar

    [150] Vitale I., Manic G., Coussens L.M., et al. (2019). Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30:36−50. DOI:10.1016/j.cmet.2019.06.001

    View in Article CrossRef Google Scholar

    [151] DeNardo D.G. and Ruffell B. (2019). Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19:369−382. DOI:10.1038/s41577-019-0127-6

    View in Article CrossRef Google Scholar

    [152] Liu Y., Dai Y. and Wang L. (2026). Spatial omics at the forefront: Emerging technologies, analytical innovations, and clinical applications. Cancer Cell 44:24−49. DOI:10.1016/j.ccell.2025.12.009

    View in Article CrossRef Google Scholar

    [153] He Y., Zhang W., Guo Z., et al. (2026). Superparamagnetic iron oxide nanoparticle restores gut microbiota homeostasis to enhance lung cancer immunotherapy. Natl. Sci. Rev. 13:nwaf565. DOI:10.1093/nsr/nwaf565

    View in Article CrossRef Google Scholar

    [154] Liu X., Fang S., Ren X., et al. (2025). GBP2 condensates promote ferroptosis to sensitize anti-PD-L1 immunotherapy in melanoma. Nat. Commun. 17:964. DOI:10.1038/s41467-025-67690-9

    View in Article CrossRef Google Scholar

    [155] Lyu Q., Liu C., Li S., et al. (2025). Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles. J. Nanobiotechnology 23:718. DOI:10.1186/s12951-025-03797-x

    View in Article CrossRef Google Scholar

    [156] Tang C., He C., Wang D., et al. (2025). Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. Nat. Commun. 16:10096. DOI:10.1038/s41467-025-65056-9

    View in Article CrossRef Google Scholar

    [157] Su G.L., Zhang M.J., Li H., et al. (2025). Dissecting tertiary lymphoid structures in cancer: Maturation, localization and density. Theranostics 15:9459−9485. DOI:10.7150/thno.113940

    View in Article CrossRef Google Scholar

    [158] Wu X., Huang Q., Chen X., et al. (2025). B cells and tertiary lymphoid structures in tumors: Immunity cycle, clinical impact, and therapeutic applications. Theranostics 15:605−631. DOI:10.7150/thno.105423

    View in Article CrossRef Google Scholar

    [159] Zhu G., Nemoto S., Mailloux A.W., et al. (2018). Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front. Immunol. 9:1609. DOI:10.3389/fimmu.2018.01609

    View in Article CrossRef Google Scholar

    [160] Argyris D.G., Johnson L., Hägglöf T., et al. (2026). Emerging involvement of CXCL13 in cancer development and progression. Cytokine Growth Factor Rev. 87:73−88. DOI:10.1016/j.cytogfr.2025.12.005

    View in Article CrossRef Google Scholar

    [161] Rodriguez A.B., Peske J.D., Woods A.N., et al. (2021). Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36:109422. DOI:10.1016/j.celrep.2021.109422

    View in Article CrossRef Google Scholar

    [162] Lei L., Long J., Chen C., et al. (2026). Tumor vasculature-mediated formation of tertiary lymphoid structures: Unraveling spatiotemporal coupling to optimize vasculo-immunotherapy. Biochem. Pharmacol. 244:117574. DOI:10.1016/j.bcp.2025.117574

    View in Article CrossRef Google Scholar

    [163] Zhang M.J., Wen Y. and Sun Z.J. (2025). The impact of metabolic reprogramming on tertiary lymphoid structure formation: Enhancing cancer immunotherapy. BMC Med. 23:217. DOI:10.1186/s12916-025-04037-7

    View in Article CrossRef Google Scholar

    [164] Xu C., Sun S., Johnson T., et al. (2021). The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 35:109235. DOI:10.1016/j.celrep.2021.109235

    View in Article CrossRef Google Scholar

    [165] Pacella I., Pinzon Grimaldos A., Rossi A., et al. (2024). Iron capture through CD71 drives perinatal and tumor-associated Treg expansion. JCI Insight 9. DOI:10.1172/jci.insight.167967

    View in Article Google Scholar

    [166] Marine J.C., Dawson S.J. and Dawson M.A. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20:743−756. DOI:10.1038/s41568-020-00302-4

    View in Article CrossRef Google Scholar

    [167] Sharma P., Hu-Lieskovan S., Wargo J.A., et al. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707−723. DOI:10.1016/j.cell.2017.01.017

    View in Article CrossRef Google Scholar

    [168] Boumahdi S. and de Sauvage F.J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19:39−56. DOI:10.1038/s41573-019-0044-1

    View in Article CrossRef Google Scholar

    [169] Zhu J.F., Guo D.P., Lv H.N., et al. (2025). Histone lactylation-mediated up-regulation of IGF2BP2 enhances ferroptosis resistance via Nrf2 in colorectal cancer. Clin. Transl. Med. 15:e70551. DOI:10.1002/ctm2.70551

    View in Article CrossRef Google Scholar

    [170] Zaretsky J.M., Garcia-Diaz A., Shin D.S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375:819−829. DOI:10.1056/NEJMoa1604958

    View in Article CrossRef Google Scholar

    [171] Clogston J.D., Foss W., Harris D., et al. (2024). Current state of nanomedicine drug products: An industry perspective. J. Pharm. Sci. 113:3395−3405. DOI:10.1016/j.xphs.2024.09.005

    View in Article CrossRef Google Scholar

    [172] Dadfar S.M., Roemhild K., Drude N.I., et al. (2019). Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 138:302−325. DOI:10.1016/j.addr.2019.01.005

    View in Article CrossRef Google Scholar

    [173] Tian J., Song X., Wang Y., et al. (2022). Regulatory perspectives of combination products. Bioact. Mater. 10:492−503. DOI:10.1016/j.bioactmat.2021.09.002

    View in Article CrossRef Google Scholar

    [174] Singh N., Jenkins G.J., Asadi R., et al. (2010). Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev. 1. DOI:10.3402/nano.v1i0.5358

    View in Article Google Scholar

    [175] Arami H., Khandhar A., Liggitt D., et al. (2015). In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem. Soc. Rev. 44:8576−8607. DOI:10.1039/c5cs00541h

    View in Article CrossRef Google Scholar

    [176] Mazuel F., Espinosa A., Luciani N., et al. (2016). Massive intracellular biodegradation of iron oxide nanoparticles evidenced magnetically at single-endosome and tissue levels. ACS Nano 10:7627−7638. DOI:10.1021/acsnano.6b02876

    View in Article CrossRef Google Scholar

    [177] Lartigue L., Alloyeau D., Kolosnjaj-Tabi J., et al. (2013). Biodegradation of iron oxide nanocubes: High-resolution in situ monitoring. ACS Nano 7:3939−3952. DOI:10.1021/nn305719y

    View in Article CrossRef Google Scholar

    [178] Xie W., Guo Z., Gao F., et al. (2018). Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic theranostics. Theranostics 8:3284−3307. DOI:10.7150/thno.25220

    View in Article CrossRef Google Scholar

    [179] Auerbach M., Chertow G.M. and Rosner M. (2018). Ferumoxytol for the treatment of iron deficiency anemia. Expert Rev. Hematol. 11:829−834. DOI:10.1080/17474086.2018.1518712

    View in Article CrossRef Google Scholar

    [180] Yang C., Li S. and Wang L. (2025). Engineered iron oxide nanoplatforms: Reprogramming immunosuppressive niches for precision cancer theranostics. Mol. Cancer 24:225. DOI:10.1186/s12943-025-02443-2

    View in Article CrossRef Google Scholar

    [181] Moloney C., Roy Chaudhuri T., Spernyak J.A., et al. (2023). Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition. Acta Biomater. 158:611−624. DOI:10.1016/j.actbio.2022.12.057

    View in Article CrossRef Google Scholar

  • Cite this article:

    Chen S., Wang H., Gan Y., et al. (2026). Iron-based materials for sequential tumor microenvironment reprogramming: From mechanical decompression to immune remodeling. The Innovation Oncology 1:100044. https://doi.org/10.59717/j.xinn-oncol.2026.100044
    Chen S., Wang H., Gan Y., et al. (2026). Iron-based materials for sequential tumor microenvironment reprogramming: From mechanical decompression to immune remodeling. The Innovation Oncology 1:100044. https://doi.org/10.59717/j.xinn-oncol.2026.100044

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

Figures(3)     Tables(5)

Supplementary Information

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(259) PDF downloads(115)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint